Fig A2.

Association between pretransplant treatment history and outcome for patients with acute myeloid leukemia (AML) undergoing myeloablative hematopoietic cell transplantation (HCT) while having active disease. Estimate of overall survival after myeloablative allogeneic HCT for adults with AML, shown individually for patients with untreated newly diagnosed (ND) disease (n = 7), patients with relapsed AML who did not undergo pre-HCT salvage chemotherapy (n = 16), and patients who experienced failure of salvage chemotherapy for either relapsed or refractory (RR) AML (n = 25).